Humana recently announced it has updated its position on stereotactic body radiation therapy (SBRT) for prostate cancer. Their medical coverage policy now covers SBRT treatment for early and intermediate stage prostate cancer.
An announcement from the CyberKnife Coalition (CKC) stated “The CyberKnife Coalition is pleased to announce that effective May 28, 2015 early stage prostate cancer patients insured by Humana will now have access to SBRT. Humana is ranked as one of the Top 10 commercial payers in the United States offering insurance plans to patients in multiple states.”
The Humana policy change follows similar updates from insurance providers and research organizations across the country that have announced support for SBRT as an appropriate treatment option for prostate cancer, after the results of numerous clinical trials and studies reinforced the safety and effectiveness of SBRT in treating prostate cancer.
At CyberKnife Center of Chicago, prostate cancer patients are treated with SBRT using CyberKnife® technology, a powerful, noninvasive treatment system that precisely focuses radiation to match the size and shape of a patient’s prostate cancer, minimizing damage to surrounding tissue.
For more information on Humana’s SRS/SBRT policy change and medically necessary criteria for SBRT treatment of prostate cancer, click here. For more information on the benefits of CyberKnife treatment, click here.